LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

31.85 -1.3

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.68

Max

32.38

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+76.58% upside

Dividenden
By Dow Jones
Volgende Winsten	13 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	956M 2.6B
Vorige openingsprijs	33.15
Vorige sluitingsprijs	31.85

Nieuwssentiment

By Acuity

50%

175 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mei 2026, 22:15 UTC

Acquisities, Fusies, Overnames

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mei 2026, 23:46 UTC

Marktinformatie

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mei 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mei 2026, 23:33 UTC

Marktinformatie

Gold Rises on Possible Position Adjustments -- Market Talk

11 mei 2026, 22:37 UTC

Marktinformatie

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mei 2026, 22:32 UTC

Winsten

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mei 2026, 22:02 UTC

Marktinformatie

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mei 2026, 21:49 UTC

Winsten

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mei 2026, 21:42 UTC

Marktinformatie

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mei 2026, 21:23 UTC

Acquisities, Fusies, Overnames

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mei 2026, 21:12 UTC

Winsten

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mei 2026, 21:12 UTC

Winsten

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

11 mei 2026, 20:44 UTC

Winsten

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mei 2026, 20:43 UTC

Winsten

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Rev $136.4M >CLSK

11 mei 2026, 20:30 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Cont Ops EPS $2.24 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Rev $1.6B >STE

11 mei 2026, 20:30 UTC

Winsten

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Adj EPS $2.83 >STE

11 mei 2026, 20:22 UTC

Populaire aandelen

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mei 2026, 19:37 UTC

Winsten

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mei 2026, 19:32 UTC

Marktinformatie

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

76.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 57 USD 76.58%

Hoogste 90 USD

Laagste 38 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

175 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.